Abstracts

717 – Nirmatrelvir/Ritonavir for Chronic COVID-19: Outcome in 16 Severely Immunocompromised Patients

Background Nirmatrelvir/ritonavir (N/r) is approved for the outpatient treatment of COVID-19 within 5 days of symptom onset and is typically used in patients at increased risk for severe disease. In severely immunocompromised patients, COVID-19 occasionally evolves into a chronic infection. The potential value of N/r in this context including optimal treatment duration is unknown. We…

657 – Intracellular Pharmacokinetics of Favipiravir-5’-Ribofuranosyl Triphosphate in People With COVID-19

Background Favipiravir (FVP) is an anti-influenza agent but preclinical data support broad spectrum antiviral activity against RNA viruses including SARS-CoV-2 and haemorrhagic fevers. Pharmacokinetic (PK) data on the active form, favipiravir ribofuranosyl-5’-triphosphate (FRTP), are lacking in humans. We measured liquid plasma (LPL) FVP and intracellular FRTP measurements in PBMC and compared this with HemaSep filter…

693 – Simplified Access and Retention Model for Vulnerable People With HIV: SIMPLIFIED Study Results

Background HIV virological suppression in vulnerable populations is influenced by various social determinants of health that affect access to healthcare. This study evaluates the feasibility and efficacy of a “test, treat, and retain” strategy implemented via street teams and a mobile unit using BIC/FTC/TAF Methods A clinical trial conducted in Madrid/Spain in 2023-2024 that included…

650 – Pharmacokinetics of Switching to B/F/TAF in PWH Post-Renal Transplant: BIK Switch Study

Background The impact of antiretroviral therapy (ART) on renal preservation is critical for persons with HIV (PWH) post-renal transplant. Clinical trials have demonstrated B/F/TAF is safe and efficacious, with low risk of renal toxicity. Little is known about its pharmacokinetics (PK) in PWH post-renal transplant.  Methods Single arm, open-label, switch study among virally suppressed (HIV…

711 – Potent, Pan-Coronavirus Antiviral Activity of the Novel 3CLpro Inhibitor ALG-097558

Background Despite widespread immunity from SARS-CoV-2 vaccination and/or past infection, safe, effective, and convenient treatments for acute infection are still needed for individuals who remain at high risk for disease progression. Moreover, the risk of another coronavirus pandemic is an ongoing threat to global health. In this context, the development of pan-coronavirus therapeutics is a…

640 – Preclinical Pharmacokinetic Assessment of a Long-Acting Solid Injectable for Hepatitis C Virus

Background Approximately 58 million people are chronically infected with HCV globally, with approximately 1.5 million new infections per year and a disproportionate burden in low- and middle-income countries. Approved oral treatments, administered over 8 – 12 weeks, are highly effective demonstrating >98% sustained virological response (SVR) in RCTs. However, in some populations intention to treat…

646 – TAF Achieves Adequate Intracellular Tenofovir-DP Concentrations With Rifampicin-Based TB Therapy

Background Co-administration of rifampicin with tenofovir alafenamide fumarate (TAF) significantly reduces plasma tenofovir and intracellular tenofovir diphosphate (TFV-DP) concentrations. Standard dose TAF with rifampicin (RIF) was associated with TFV-DP concentrations that were markedly higher than those observed with tenofovir disoproxil fumarate (TDF) without rifampicin in healthy volunteers, however, data from people with TB/HIV-1 are needed…

651 – Tenofovir Diphosphate in Dried Blood Spots and HIV-1 RNA Suppression Among PWH on TAF (ACT Study)

Background ACT (NCT05335590) is an ongoing observational study that aims to evaluate tenofovir-diphosphate (TFV-DP) concentrations in dried blood spots (DBS) among persons with HIV (PWH) receiving tenofovir alafenamide (TAF)-based antiretroviral therapy (ART) with suppressed compared with detectable HIV-1 RNA. Previously, QUANTI-TAF (NCT04065347) reported a pharmacokinetic (PK)-based TFV-DP in DBS benchmark of ≥1800 fmol/punches for PWH…

639 – First-in-Human Study of a Long-Acting Injectable 3 Antiretroviral Drug Combination Nanoparticle

Background Long-Acting antiretroviral therapy (LA-ART) is considered an integral tool to improve adherence and decrease stigma, but its global implementation has met barriers, including cost and resources for administration. The TLC-ART program, a public-private partnership, engineered a novel 3-drug combination nanoparticle (DcNP) for subcutaneous injection containing lopinavir (LPV), ritonavir (RTV), and tenofovir (TVF) “TLC-ART 101” bound…